Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma.

Boussemart, Lise; Johnson, Adrienne; Schrock, Alexa B; Pal, Sumanta K; Frampton, Garrett M; Fabrizio, David; Chalmers, Zachary; Lotem, Michal; Gibney, Geoffrey; Russell, Jeffery; Chmielowski, Bartosz; Ross, Jeffrey S; Stephens, Phil J; Miller, Vincent A; Ali, Siraj M

Boussemart, Lise; Johnson, Adrienne; Schrock, Alexa B; Pal, Sumanta K; Frampton, Garrett M; Fabrizio, David; Chalmers, Zachary; Lotem, Michal; Gibney, Geoffrey; Russell, Jeffery; Chmielowski, Bartosz; Ross, Jeffrey S; Stephens, Phil J; Miller, Vincent A; Ali, Siraj M.

Afiliação

Boussemart L; Department of Dermatology, Pontchaillou Hospital, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France; Université Rennes, Centre National de la Recherche Scientifique, Institut de Génétique and Développement de Rennes, UMR 6290, F-35000 Rennes, France.
Johnson A; Foundation Medicine Inc, Cambridge, Massachusetts.
Schrock AB; Foundation Medicine Inc, Cambridge, Massachusetts.
Pal SK; Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California.
Frampton GM; Foundation Medicine Inc, Cambridge, Massachusetts.
Fabrizio D; Foundation Medicine Inc, Cambridge, Massachusetts.
Chalmers Z; Foundation Medicine Inc, Cambridge, Massachusetts.
Lotem M; Department of Oncology, Hadassah Medical Center, Jerusalem, Israel.
Gibney G; Georgetown-Lombardi Comprehensive Cancer Center, Washington DC.
Russell J; Moffitt Cancer Center, Tampa, Florida.
Chmielowski B; Department of Medicine, Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles, California.
Ross JS; Foundation Medicine Inc, Cambridge, Massachusetts; Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York.
Stephens PJ; Foundation Medicine Inc, Cambridge, Massachusetts.
Miller VA; Foundation Medicine Inc, Cambridge, Massachusetts.
Ali SM; Foundation Medicine Inc, Cambridge, Massachusetts. Electronic address: sali@foundationmedicine.com.

J Am Acad Dermatol ; 80(6): 1780-1782, 2019 06.

Article em En | MEDLINE | ID: mdl-30576761

Assuntos

Proteínas Reguladoras de Apoptose/efeitos dos fármacos; Proteínas Reguladoras de Apoptose/genética; Melanoma/tratamento farmacológico; Melanoma/genética; Neoplasias Cutâneas/tratamento farmacológico; Neoplasias Cutâneas/genética; Adulto; Idoso; Idoso de 80 Anos ou mais; Estudos de Coortes; Análise Mutacional de DNA; Feminino; Estudo de Associação Genômica Ampla; Humanos; Ipilimumab/administração & dosagem; Masculino; Melanoma/mortalidade; Melanoma/patologia; Pessoa de Meia-Idade; Terapia de Alvo Molecular/métodos; Invasividade Neoplásica; Metástase Neoplásica; Estadiamento de Neoplasias; Prognóstico; Estudos Retrospectivos; Medição de Risco; Neoplasias Cutâneas/mortalidade; Neoplasias Cutâneas/patologia; Resultado do Tratamento; Melanoma Maligno Cutâneo

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Proteínas Reguladoras de Apoptose / Melanoma Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Am Acad Dermatol Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google